Adaptimmune Therapeutics Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Adaptimmune Therapeutics Plc (ADAP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Adaptimmune Therapeutics Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 65M vs 84,359M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-15.9% annualized vs trailing 12 months), vs decelerating (-17.6%) for its tracked peer group.
- Growth: Adaptimmune Therapeutics Plc generated -89.3% revenue growth year over year in Q2 2025, vs 4.9% for its competitors combined.
- Profitability: Its -221.8% net margin compares with 12.5% for the peer group.
- Peer revenue share: Adaptimmune Therapeutics Plc accounted for 0.1% of combined revenue among its tracked peer group, down from 0.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.26M compares with $1.93M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ADAP Sales vs. its Competitors, Q2 2025
Adaptimmune Therapeutics Plc reported revenue contraction of 89.33 % year on year in Q2 2025, below its competitors' combined revenue growth of 4.94 %.
With a net margin of -221.83 %, Adaptimmune Therapeutics Plc reported lower profitability than its competitors (12.49 %).
Adaptimmune Therapeutics Plc generated 0.08 % of the combined sales of its peer group, down from 0.77 % a year earlier.
API endpoints for this dataset
Adaptimmune Therapeutics Plc vs. its Competitors, Q2 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Adaptimmune Therapeutics Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Adaptimmune Therapeutics Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Adaptimmune Therapeutics Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (12) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Adaptimmune Therapeutics Plc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.8% year over year, combined, vs -89.3% for Adaptimmune Therapeutics Plc. Adaptimmune Therapeutics Plc's share of combined industry revenue moved from 0.34% to 0.03%, a loss of 0.31 percentage points.
Adaptimmune Therapeutics Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Adaptimmune Therapeutics Plc | - | No | No | Yes |
| Competitors combined (56) | ||||
| High-Confidence Competitors (14) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ADAP Stock Performance relative to its Competitors
ADAP Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Century Therapeutics inc | 282.9% | Outperformed |
| 3 | Replimune Group Inc | 282.9% | Outperformed |
| 4 | Exelixis Inc | 282.9% | Outperformed |
| 5 | Agenus Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Adaptimmune Therapeutics Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Adaptimmune Therapeutics Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Adaptimmune Therapeutics Plc |
86.99 | 65.09 |
 Amgen Inc |
250,392.32 | 38,095.00 |
 Gilead Sciences Inc |
209,630.07 | 30,988.00 |
 Moderna Inc |
96,101.08 | 2,228.00 |
 Argenx Se |
59,080.96 | 8,399.37 |
 Exelixis Inc |
17,572.86 | 2,496.86 |
| SUBTOTAL | 648,200.82 | 84,787.92 |
Sign in to see all competitors of Adaptimmune Therapeutics Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Adaptimmune Therapeutics Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Adaptimmune Therapeutics Plc's Competitors Named by the Company
Competitive relationships identified from Adaptimmune Therapeutics Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Phoenix Biotech Acquisition Corp | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Immunocore Holdings Plc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Abecma TM | Company report | 85% |
| Samsara Luggage Inc | Company report | 85% |
| Tecartus TM | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Instil Bio Inc | Company report | 85% |
| Breyanzi TM | Company report | 85% |
| Yescarta TM | Company report | 85% |
| CARVYTKI TM | Company report | 85% |
| Allogene Therapeutics | Company report | 85% |
| Fate Therapeutics Inc. | Company report | 85% |
| Takeda Pharmaceuticals Limited | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| RENB | Company report | 85% |
| Celularity Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Senti Biosciences Holdings Inc | Company report | 85% |
| Poseida Therapeutics Inc | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Lyell Immunopharma Inc | Company report | 85% |
| 2seventy Bio Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Tcr2 Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Adaptimmune Therapeutics Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Adaptimmune Therapeutics Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Lyell Immunopharma Inc | Reportable segment 100.00 % |
| Autolus Therapeutics Plc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | 87 | 264,573 | -690,065 |
| Amgen Inc | 250,392 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 209,630 | 1,822,824 | -227,235 |
| Moderna Inc | 96,101 | 474,043 | -670,426 |
| Argenx Se | 59,081 | 7,316,521 | 1,125,466 |
| Exelixis Inc | 17,573 | 2,176,862 | 1,454,397 |
| PEERS TOTAL | 648,114 | 1,925,213 | 41,607 |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Exelixis Inc | United States 92.47 % |
| Novocure Limited | United States 57.86 % |
| Agenus Inc | US 100.00 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Adaptimmune Therapeutics Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Adaptimmune Therapeutics Plc's industry classification, broader than the peer set above. Market cap in millions of $.Adaptimmune Therapeutics Plc ranks #0 of 158 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,384, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 250,392 | 26.45 % |
| 2 | Gilead Sciences Inc | 208,290 | 22.00 % |
| 3 | Moderna Inc | 96,101 | 10.15 % |
| 4 | Argenx Se | 59,081 | 6.24 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 0 | Adaptimmune Therapeutics Plc | 87 | 0.00 % |
Market cap and industry share for the rest of Adaptimmune Therapeutics Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-10-27.
Adaptimmune Therapeutics Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (159 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 24.46 % | 35.06 % (avg) | -10.6 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -2.95 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 3.07 % | 8.95 % (avg) | -5.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Adaptimmune Therapeutics Plc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 28.3x | - |
| EV / EBITDA | - | 17.6x | - |
| P/B | -102.6x | 5.1x | -107.7x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | -105.88 % | -12.21 % (avg) | -93.67 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Adaptimmune Therapeutics Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 166.47 % | 57.28 % | -164.18 % | - | 209.86 % | 295.51 % | 110.11 % | 195.34 % |
| Operating Margin | -213.20 % | -138.42 % | 365.98 % | -2,127.33 % | -1,661.10 % | - | - | -38.62 % |
| Return on Invested Capital | -17.95 % | -18.55 % | -38.44 % | -18.42 % | -24.44 % | -38.43 % | -39.26 % | -25.26 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Adaptimmune Therapeutics Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,384 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.07 % vs industry average 8.95 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Adaptimmune Therapeutics Plc's dedicated Suppliers and Customers pages, not here.
Adaptimmune Therapeutics Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-15.9% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (64.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-17.6% annualized).
Methodology: see Methodology: SWOT Analysis.
Adaptimmune Therapeutics Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | 1.19 | 2.66 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Argenx Se | 2.64 | 5.23 | - |
| Exelixis Inc | 0.84 | 3.37 | - |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Adaptimmune Therapeutics Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | Q2 2025 | -89.3 % | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Argenx Se | Q4 2025 | +89.1 % | +55.1 % |
| Exelixis Inc | Q3 2026 | +10.2 % | -51.1 % |
| PEERS TOTAL | +25.4 % | +26.7 % |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Adaptimmune Therapeutics Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | Q2 2025 | - | -91.2 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Argenx Se | Q4 2025 | +44.6 % | +242.3 % |
| Exelixis Inc | Q3 2026 | +41.2 % | +67.9 % |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Moderna Inc | - | - | - |
| Argenx Se | 14.88% | 14.81% | 17.64% |
| Exelixis Inc | 63.88% | 75.01% | 85.83% |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Adaptimmune Therapeutics Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Adaptimmune Therapeutics Plc | - | 1.34 |
| Amgen Inc | 28.59 | 6.57 |
| Gilead Sciences Inc | - | 6.76 |
| Moderna Inc | - | 43.13 |
| Argenx Se | 45.72 | 7.03 |
| Exelixis Inc | 28.28 | 7.04 |
| PEERS AVERAGE | 390.19 | 7.64 |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.